Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy

International Journal of Cancer

Volumn 110, Issue 2, 2004, Pages 260-265

  Kedar, Igal ^a,b   Mermershtain, Wilmosh ^a   Ivgi, Hefziba ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Soroka University Medical Center   (Israel)

Author keywords

Acute phase reactants; Biologic therapy; Immune suppression

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; THALIDOMIDE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CACHEXIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SOMNOLENCE;

ADULT; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 2342515336     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20089     Document Type: Article

References (30)

1. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283-95.
2. Rosenberg SA, Lotz MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with LAK cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
3. Blay JY, Negrier S, Combart V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF. Serum levels of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
4. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman WH. Predictors of clinical response to Interleukin-2 based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996;14:1697-703.
5. Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J. Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 1995;99:143-7.
6. Thioun N, Pages F, Flan I, Tartour E, Mosseri V, Zerbib M, Beuzeboc P, Deneux L, Fridman WH, Debre B. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett 1997;58:121-4.
7. Warren RS, Starnes HF Jr, Gabrilove J, Oeegen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396-400.
8. Poli V, Cortese R. Inerleukin-6 induces a liver specific nuclear that binds to the promotion of acute phase genes. Proc Natl Acad Sci USA 1989;86:8202-6.
9. Bauman H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-88.
10. Lee J, Vilcek J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-601.
11. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-2 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993;83:433-41.
12. Miki S, Iwano M, Yamamoto M, Tang B, Yokowawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett 1989;250: 607-10.
13. Wu S, Boyer CM, Witaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC Jr. Tumor necrosis factor α as an outcome and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor α expression. Cancer Res 1993;53:1939-44.
14. Tadamitsu K, Shizuo A, Tetsuya T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593-6.
15. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993;50:15-9.
16. Botti C, Seregni E, Ferrari L, Martinetti A, Bomadieri E. Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers 1998;13:51-5.
17. Elgert KD, Alleva DG, Mullins DW. Tumor induced dysfunction: the macrophage connection. J Leukoc Biol 1998;64:275-8.
18. Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 1999;47:83-7.
19. Sampaio EP, Sarno EN, Gallili R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits TNF alfa production by stimulated human macrophages. J Exp Med 1991;173:699-703.
20. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G. Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
21. Gez E, Rubinov R, Gaitini D, Meretyk S, Best LA, Native O, Stein A, Erlich N, Beny A, Zidan J, Haim N, Kuten A. Interleukin-2 interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma. Cancer 2002;95:1644-9.
22. Lopez HE, Kirshner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
23. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem cell transplantation. N Engl J Med 2000;343:750-8.
24. Bariogie B, Zangari M, Spencer T, Fassas A, Analssie E, Badros A, Cromer J, Tricot G. Thalidomide in the management of multiple myeloma. Semin Hematol 2001;38:250-9.
25. Bertolini F, Mingrone W, Alieti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001;12:987-90.
26. Stebbing J, Benson C, Eisen T, Pyle L, Smally K, Bridle H, Mak I, Sapunar F, Aharn R, Gore ME. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001;85:953-8.
27. Motzer RG, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;20:302-6.
28. Person RT, Kronich K, Duan Z, Feller AJ, Stark P, et al. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41.
29. Eskandari N, Gage J, Johnson MT, Martinez-Maza O. Cytokine-mediated modulation of Cisplatin sensitivity in ovarian cancer cells. Obstet Gynecol 2001;S2(Suppl):S2.
30. Borsellino N, Belldegrun A, Bonavida B. Endogenous Interleukin-6 is a resistance factor for cis -diaminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-9.